Background and Objectives: Malignant pleural mesothelioma (MPM) is reported to be common in the southeast of Turkey, as a result of environmental asbestos exposure. The aim of this study was to evaluate the computed tomography (CT) features of MPM in patients with a history of asbestos exposure. Methods: The CT scans of 117 patients who had a diagnosis of MPM were retrospectively evaluated. Additionally, CT findings of histologic subtypes were compared. Results: The most common CT findings included pleural effusion (n = 104, 89%), pleural thickening (n = 96, 82%), mediastinal pleural involvement (n = 77, 66%) and interlobar fissural involvement (n = 62, 53%). Histologic subtype analysis was performed in 89 patients; of these, epithelial, sarcomatous and mixed types were identified in 46, 23 and 20 patients, respectively. An analysis of CT findings demonstrated that the involvement of mediastinal pleural (91%), interlobar fissure (87%) and lung parenchyma (48%) was significantly more frequent in sarcomatous type, as compared to epithelial (61% and p < 0.01; 35 and 4%, p < 0.0001, respectively) and mixed types (65% and p < 0.05; 10% and p < 0.0001; 10% and p < 0.01, respectively). Furthermore, there was a significant correlation between pericardial involvement and chest wall involvement (r = 0.42, p < 0.05) in sarcomatous type. Similarly, lymphadenopathy and parenchymal involvement (r = 0.23, p < 0.02), pericardial and chest wall involvement (r = 0.25, p < 0.01), chest wall and interlobar fissural involvement (r = 0.25, p < 0.01) were significantly correlated, when CT findings of all histologic subtypes were combined. Conclusions: These results suggest that although CT findings of MPM vary, they may provide valuable clues to the diagnosis, at least in patients with a history of asbestos exposure. In addition, the presence of extensive lesions may suggest MPM of sarcomatous subtype.

Keywords:
Mesothelioma, Computed tomography, Environmental asbestos exposure
1.
Patz EF Jr, Shaffer K, Piwnica-Worms DR, Jochelson M, Sarin M, Sugarbaker DJ, Pugatch RD: Malignant pleural mesothelioma: Value of CT and MR imaging in predicting resectability. AJR 1992;159:961–966.
2.
Aisner J: Current approach to malignant mesothelioma of the pleura. Chest 1995;107(suppl):332–344.
3.
Selçuk ZT, Çöplü L, Emri S, Kalyoncu AF, Şahin AA, Barış Yi: Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey: Analysis of 135 cases. Chest 1992;102:790–796.
4.
Nishimura SL, Broaddus VC: Asbestos-induced pleural disease. Clin Chest Med 1998;19:311–329.
5.
Türler A, Mönig SP, Raab M: Problems in diagnosis and therapy of malignant pleural mesothelioma. Med Klin 1997;92:101–105.
6.
Şahin AA, Çöplü L, Selçuk ZT, Eryılmaz M, Emri S, Akhan O, Barış Yi: Malignant pleural mesothelioma caused by environmental exposure to asbestos or erionite in rural Turkey: CT findings in 84 patients. AJR 1993;161:533–537.
7.
Yılmaz UM, Utkaner G, Yalnız E, Kumcuoglu Z: Computed tomographic findings of environmental asbestos-related malignant pleural mesothelioma. Respirology 1998;3:33–38.
8.
Yazıcıoğlu S: Pleural calcification associated with exposure to chrysotile asbestos in Southeast Turkey. Chest 1976;70:43–47.
9.
Yazıcıoğlu S, ilçayto R, Balcı K, Saylı BS, Yorulmaz B: Pleural calcification, pleural mesotheliomas, and bronchial cancers caused by tremolite dust. Thorax 1980;35:564–569.
10.
Topçu F, Bayram H, Şimşek M, Kaya K, Özcan C, Işık R, Şenyiğit A: High-resolution computed tomography in cases with environmental exposure to asbestos in Turkey. Respiration 2000;67:139–145.
11.
Adams VI, Unni KK, Muhm JR, Jett JR, Ilstrup DM, Bernatz PE: Diffuse malignant mesothelioma of pleura. Diagnosis and survival in 92 cases. Cancer 1986;58:1540–1551.
12.
Işık R, Şimşek M, Coşkunsel M, Bükte Y: CT findings in diagnosis of malignant mesothelioma. Tüberküloz ve Toraks 1993;41:45–50.
13.
Leung AN, Müller NL, Miller RR: CT in differential diagnosis of diffuse pleural disease. AJR 1990;154:487–492.
14.
Erzen C, Eryılmaz M, Kalyoncu F, Bilir N, Şahin A, Barış Yi: CT findings in malignant pleural mesothelioma related to nonoccupational exposure to asbestos and fibrous zeolite (erionite). J Comput Assist Tomogr 1991;15:256–260.
15.
Rusch VW, Godwin JD, Shuman WP: The role of computed tomography scanning in the initial assessment and the follow-up of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1988;96:171–177.
16.
Bilici A, Uyar A, Özateş M: CT features of malignant pleural mesothelioma. Dicle Üniv Tıp Fak Derg 1994;21:35–44.
17.
Alexander E, Clark AC, Colley DP, Mitchell SE: CT of malignant pleural mesothelioma. AJR 1981;137:287–291.
18.
Rabinowitz JG, Efremidis SC, Cohen B, Dan S, Efremidis A, Chahinian AP, Teirstein AS: A comparative study of mesothelioma and asbestosis using computed tomography and conventional chest radiography. Radiology 1982;144:453–460.
19.
Maffessanti M, Tommasi M, Pellegrini P: Computed tomography of free pleural effusions. Eur J Radiol 1987;7:87–90.
20.
Gevenois PA, Trogrlic S: Imaging of the pleura. Rev Prat 1997;47:1304–1307.
21.
Miller WT Jr, Gefter WB, Miller WT Sr: Asbestos-related chest diseases: Plain radiographic findings. Semin Roentgenol 1992;27:102–120.
22.
Çakmak F, Kuranel BB, Ünsal M, Işık S: Computed tomographic findings in malignant pleural mesothelioma. Solunum Hastalıkları 1993;4:31–39.
23.
Kawashima A, Libshitz HI: Malignant pleural mesothelioma: CT manifestations in 50 cases. AJR 1990;155:965–969.
24.
Munden RF, Libshitz HI: Rounded atelectasis and mesothelioma. AJR 1998;170:1519–1522.
25.
Albelda SM, Sterman DH, Litzky LA: Malignant mesothelioma and other primary pleural tumors; in Fishman AP (ed): Fishman’s Pulmonary Diseases and Disorders. New York, McGraw-Hill, 1998, pp 1453–1466.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.